The Latest Analyst Ratings for Harmony Biosciences
Portfolio Pulse from Benzinga Insights
Harmony Biosciences (NASDAQ:HRMY) has received 5 bullish analyst ratings in the last quarter, with no bearish or indifferent ratings. The average 12-month price target for the company is $68.8, a decrease of 8.27% from the previous average of $75.00.

August 04, 2023 | 10:34 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Harmony Biosciences has received positive analyst ratings, which could boost investor confidence. However, the decrease in the average price target could indicate a potential downside.
Analyst ratings can influence investor sentiment and stock prices. The bullish ratings for Harmony Biosciences indicate a positive outlook, which could attract investors and potentially drive the stock price up. However, the decrease in the average price target suggests that analysts expect the stock price to decrease in the future, which could deter some investors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100